Document and Entity Information
Document and Entity Information | May 18, 2020 |
Cover [Abstract] | |
Amendment Flag | true |
Entity Central Index Key | 0001479290 |
Document Type | 8-K/A |
Document Period End Date | May 18, 2020 |
Entity Registrant Name | Revance Therapeutics, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-36297 |
Entity Tax Identification Number | 77-0551645 |
Entity Address, Address Line One | 7555 Gateway Boulevard |
Entity Address, City or Town | Newark |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94560 |
City Area Code | (510) |
Local Phone Number | 742-3400 |
Written Communications | true |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.001 per share |
Trading Symbol | RVNC |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | Revance Therapeutics, Inc. is filing this Amendment No. 1 to its Current Report on Form 8-K, originally filed on May 19, 2020 (the “Original Filing”), solely to correct a typographical error in the Original Filing. The Original Filing incorrectly stated that eight million four hundred and fifty thousand (8,450,000) shares would be used in the calculation of the Merger Shares (as defined in the Original Filing). The correct number is eight million five hundred and forty thousand (8,540,000) shares. No other changes have been made to the Original Filing. |